: As uncertainty looms large in Afghanistan, Indian pharma exporters are apprehensive to send goods to the war-torn country and the target of exporting USD 126 million worth of pharmaceutical goods to the Taliban-ruling nation now depends on the future outcome.
Udaya Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India (Pharmexcil) body under the Department of Commerce on Tuesday said as the situation is grim over there and India pharma exporters have cordial relations with Afghanistan.
"The projected target for 2021-22 is USD 126.22 million. The majority of it would be formulations and after that vaccines. Now with the present situation, exporters are apprehensive with regards to how the new regime will act upon. It is too early to comment on export targets," the official told PTI on Tuesday.
He, however, said there was no instruction from the centre to suspend exports to Afghanistan.
According to the statistics supplied by Pharmexicl, India exported nearly USD 90 million and USD 97 worth of pharma products to Afghanistan in 2019-20 and 2020-21 respectively and became the second largest exporter after Pakistan.
Afghanistan has accepted Indian Pharmacopeia and the drugs manufactured in India are accepted there, Udaya Bhaskar said.
"A team of Afghan officials and trade representatives visited and held discussions with their counterparts in India in 2019 stemming the cordial relations," he said.
Federation of Indian Export Organisations (FIEO) Director General Ajay Sahai recently said domestic exporters should follow caution looking into the political development in Afghanistan, particularly with regard to payments, for which adequate credit insurance may be availed by them.
According to a pharma trade expert, Indian pharma exports comprises 20 per cent vaccines. Though Afghanistan does not receive all its required vaccines from India directly, several non-governmental organisations procure them from Indian firms and send them to that country.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)